Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510811 | 0.92 | PIK3CG (0.37) | PIK3CGP2RX7WDR5KMT2A | |
| SCHEMBL2510495 | 0.90 | PIK3CG (0.36) | PIK3CGP2RX7WDR5KMT2A | |
| SCHEMBL2511459 | 0.89 | PIK3CG (0.35) | PIK3CGP2RX7WDR5KMT2A | |
| SCHEMBL2511909 | 0.88 | ALDH1A1 (0.40) | PIK3CGP2RX7 | |
| SCHEMBL2507370 | 0.80 | IDH1 (0.33) | WDR5KMT2A | |
| SCHEMBL2511074 | 0.75 | PARP1 (0.32) | P2RX7 | |
| SCHEMBL2511462 | 0.74 | CRBN (0.36) | WDR5KMT2A | |
| SCHEMBL2509719 | 0.73 | IDH1 (0.36) | P2RX7WDR5KMT2A | |
| SCHEMBL2510491 | 0.70 | PIK3CG (0.46) | PIK3CGSIK2 | |
| SCHEMBL12442781 | 0.65 | CHEK2 (0.42) | PIK3CGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | claimed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | PIK3CG 3558/4885P2RX7 463/4885WDR5 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.